Nifurtimox

證據等級: L5

預測適應症: 7 個

Nifurtimox: From Chagas Disease to Congenital Analbuminemia

One-Sentence Summary

Nifurtimox is a nitrofuran-class antiparasitic historically used to treat Chagas disease (American trypanosomiasis) and, in combination therapy, African trypanosomiasis. The TxGNN model predicts a possible link to Congenital Analbuminemia, but this prediction is currently supported by zero clinical trials and zero publications — it is a model-only signal with no identifiable biological rationale.

Quick Overview

Item	Content
Original Indication	Chagas disease (American trypanosomiasis) — based on known drug identity; no Taiwan/US license records are present in this Evidence Pack
Predicted New Indication	Congenital Analbuminemia
TxGNN Prediction Score	99.58%
Evidence Level	L5
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, nifurtimox belongs to the nitrofuran class of antiparasitic agents; its efficacy in Chagas disease has been established, acting through nitroreductase-mediated activation to generate free radicals/oxidative stress and inhibit trypanothione reductase in the parasite.

Congenital analbuminemia is a monogenic disorder (ALB gene defect) causing a hepatic protein-synthesis deficiency — a pathophysiology with no known overlap with antiparasitic oxidative-stress mechanisms. The evidence pack’s own mechanistic assessment concludes there is no identifiable biological pathway connecting nifurtimox’s pharmacology to this disease, and judges the high TxGNN score as most likely a knowledge-graph embedding coincidence rather than a genuine mechanistic signal.

Notably, six other TxGNN-predicted indications for this drug (polyclonal hyperviscosity syndrome, hyperamylasemia, blood group incompatibility, monoclonal gammopathy, premalignant hematological disease, and hematological disease associated with acquired peripheral neuropathy) were also screened, all scoring similarly high (~99%) with equally weak or absent mechanistic support. One of these — peripheral neuropathy-associated hematological disease — is flagged as a potential inverse signal, since peripheral neuropathy is a known adverse effect of nifurtimox, and the model may have learned a drug-causes-disease association rather than a treatment relationship.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

US Market Information

Nifurtimox is not currently marketed and no NDA/license records are present in this Evidence Pack (taiwan_regulatory.total_licenses = 0).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is high, but it is unsupported by any clinical trial, literature, or plausible mechanistic link (Evidence Level L5, model prediction only). A TFDA label/warnings data gap is also flagged as Blocking, meaning safety cannot be assessed at all for this candidate.

To proceed, the following is needed:

TFDA-equivalent label data (warnings, contraindications) — currently a Blocking data gap
Confirmed original mechanism of action (MOA) from DrugBank or primary literature
Preclinical or case-level evidence establishing a biological rationale for congenital analbuminemia specifically
Re-evaluation of the peripheral-neuropathy-associated candidate to rule out an inverse (adverse-effect) signal before any further screening
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.